Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-tumour necrosis factor alpha therapy: can we afford it?

× No keyword cloud information.

16 in total

Review 1. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

Authors: P Jobanputra; P Barton; S Bryan; A Burls
Journal: Health Technol Assess Date: 2002 Impact factor: 4.014

2. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

3. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Authors: Lars Klareskog; Désirée van der Heijde; Julien P de Jager; Andrew Gough; Joachim Kalden; Michel Malaise; Emilio Martín Mola; Karel Pavelka; Jacques Sany; Lucas Settas; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad; Marie Sanda
Journal: Lancet Date: 2004-02-28 Impact factor: 79.321

4. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.

Authors: Samantha L Hider; Caitriona Buckley; Alan J Silman; Deborah P M Symmons; Ian N Bruce
Journal: J Rheumatol Date: 2005-01 Impact factor: 4.666

5. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

Authors: Andreas Maetzel; Peter Tugwell; Maarten Boers; Francis Guillemin; Doug Coyle; Mike Drummond; John B Wong; Sherine E Gabriel
Journal: J Rheumatol Date: 2003-04 Impact factor: 4.666

6. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

Authors: A Kavanaugh; E W St Clair; W J McCune; T Braakman; P Lipsky
Journal: J Rheumatol Date: 2000-04 Impact factor: 4.666

7. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

Authors: N J Bansback; A Brennan; O Ghatnekar
Journal: Ann Rheum Dis Date: 2004-11-18 Impact factor: 19.103

8. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.

Authors: G Kobelt; K Eberhardt; P Geborek
Journal: Ann Rheum Dis Date: 2004-01 Impact factor: 19.103

9. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

Authors: A Brennan; N Bansback; A Reynolds; P Conway
Journal: Rheumatology (Oxford) Date: 2003-07-30 Impact factor: 7.580

10. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors: Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal: Arthritis Rheum Date: 2003-01

1 in total

1. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.

Authors: Hilary A Capell; Rajan Madhok; Duncan R Porter; Robin A L Munro; Iain B McInnes; John A Hunter; Malcolm Steven; Asad Zoma; Elaine Morrison; Martin Sambrook; Fat Wui Poon; Rosemary Hampson; Fiona McDonald; Ann Tierney; Neil Henderson; Ian Ford
Journal: Ann Rheum Dis Date: 2006-08-22 Impact factor: 19.103

1 in total